Publicador de contenidos

Investigación

P4COPD

Prediction, Prevention, Personalized and Precision management of COPD in young adults

COPD
Foto: Canva
Duración
01/01/2022 - 31/12/2025
Coordinador
Alvar Agusti (Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS)
Financiadores
Instituto de Salud Carlos III (ISCIII), cofinanciado por la "Unión Europea NextGenerationEU/Mecanismo para la Recuperación y la Resilencia (MRR)/PRTR” (PMP21/90)

Chronic Obstructive Pulmonary Disease (COPD) is a major health problem because of its high prevalence, morbidity and mortality (currently 3rd global cause of death). Traditionally, it was considered only as a smoking related disease occurring in old individuals. However, it has recently been shown that COPD is actually the end result of dynamic and cumulative gene-environment interactions starting early in life.

This opens new opportunities for the prediction, prevention, personalized and precise management (P4) of COPD in young adults, which will help to promote healthy ageing.

The objectives of P4COPD are:

  • To investigate the genomic and environmental/lifestyle determinants of COPD in young adults (20-50 years).
  • To contrast them with those determined in children, adolescent and older individuals.
  • To explore the feasibility and cost of implementing in clinical practice a P4 strategy for COPD in young adults.

 

To achieve these objectives, P4COPD will extend and update already existing cohorts of young subjects (20-50 years) in whom we will:

  • Analyze demographic, epidemiological, clinical and physiologic information.
  • Measure genetic, epigenetic and proteomic markers.
  • Use advanced computer analytical methods to identify endotypes, biomarkers and potential therapeutic targets associated with the presence of COPD.

These results in young individuals will be contrasted with general population and COPD cohorts in older patients.

Besides, we will explore how to implement this P4 medicine approach in clinical practice through the development of an individual COPD risk calculator, design and test educational activities and estimate its potential health cost implications.

Total funding

1,998,700 €

Nuestro equipo

Coordinator

  • Alvar Agusti (Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS)
    Alvar Agusti (Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS)

ISGlobal Principal Investigators

ISGlobal Team

Ver más